ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers
An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Listed as NCT02657876, this PHASE1 trial focuses on Diabetes and Diabetic Foot Ulcer and remains completed. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
Status: Recruiting → Not Yet Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Stratatech, a Mallinckrodt Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Pittsburgh, United States